© РИА Томск. Павел Стефанский TOMSK, Sep 21 – RIA Tomsk.
Scientists of the Institute for Problems of Chemical and Energetic Technologies
(IPCET) SB RAS (Biysk) with the assistance of colleagues from Tomsk State University (TSU) developed medicine for treatment with lack of side effect;
glyoxal became raw materials for medicine, the press service of the higher
education institution reported on Wednesday.
Glyoxal is a substance which industrial
technology of synthesis is developed by chemists of TSU. In 2009 in Tomsk the
Russian Federation's first glyoxal production plant was opened. It is used for
production of new generation of rocket fuel, medical supplies and thousands of
other materials and substances.
"High-energy compounds are also made on
the basis of glyoxal. We withdraw a small part of substance at the intermediate
stage of synthesis, finish it and receive medicine with fine pharmacological
characteristics", – the director of IPCET SB RAS Sergey Sysolyatin is quoted
in the message.
© сайт Томского государственного университета
It is specified that on the basis of the Tomsk
scientific research institute of pharmacology and regenerative medicine
preclinical tests of the new medicine – tiovurcin were carried out. They showed
that the medicine stops pains of various origin, has longer period of action,
than other anesthetics of medicine, but at the same time it doesn't make toxic
impact on an organism.
"According to the expert opinion,
tiovurcin conforms to the requirements of the fourth class of danger –
"low-dangerous substances". Extent of its toxic impact on an organism
is comparable unless with a hyperalimentation. At long injection of drug (28
days) medicinal dependence doesn't develop, there is no influence on
respiration, there is no stimulating effect on the central nervous
system", – it is said in the report.
Preclinical testing of the new medicine are on
a closing stage. The patent for the development is already taken out. The joint
project of the Biysk and Tomsk scientists is planned to be realized within the
Pharma 2020 program.